Dr Josep Ribera talks to ecancer at the ALL Assembly 2018 Meeting in Amsterdam about the how to best use TKIs in Ph-positive ALL.
Dr Ribera states that it's possible that using TKIs (tyrosine kinase inhibitors) could become the standard for treating Ph-positive ALL patients.
He also outlines several promising strategies for treating patients suffering with relapsed refractory ALL.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.